Strategic Partnerships Spexis is actively pursuing collaborations and asset acquisitions, evidenced by the January 2024 asset purchase with Basilea Pharmaceutica and ongoing funding partnerships, presenting sales opportunities to market and co-developColiFin® and related respiratory therapies.

Orphan Drug Advantage ColiFin® in the U.S. has Orphan Drug and QIDP designations, offering 12 years of market exclusivity post-NDA, which can be a compelling value proposition to payers and distributors when negotiating launches and co-promotion deals.

Phase 3 Readiness A FDA Study May Proceed letter and CFF TDN endorsement for ColiFin® single Phase 3 study provide a clearer regulatory path and risk profile, enabling targeted conversations with CROs, site networks, and specialty distributors for expedited access.

CRD Focus Spexis targets chronic respiratory diseases with ColiFin®, offering a concentrated entry point for specialty pharmacies and respiratory care channels, including CF clinics and hospital networks seeking front-line inhaled therapies.

Financial Leverage Recent multi-funder support including a USD 2.5M financing and convertible note arrangements indicate readiness for accelerated trials; this creates gateways to financial partners, co-marketing funds, and payer value demonstrations to accelerate commercialization.